RxDoctor Payments Data

Tracey Royer

Family · White Plains, MDNPI 1225401227

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,773 of the $16,717 with a category attached, or 82.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,717in general payments, 2019–2025

Across 582 payments — averaging $28.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Merck$1K
  • Johnson & Johnson$1K
  • Pfizer$685
  • AstraZeneca$669
  • Astellas Pharma US Inc$484
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$13,77382%
  • Education$9145%
  • Other$2,03012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis55$2,769
Merck44$1,132
Johnson & Johnson43$1,011
Pfizer28$685
AstraZeneca(2 entities)30$669
Astellas Pharma US Inc16$484
Lilly USA, LLC12$413
AVEO Pharmaceuticals, Inc.8$411
Genentech USA, Inc.17$411
Bristol Myers Squibb10$405
Daiichi Sankyo Inc.14$404
Takeda Pharmaceuticals U.S.A., Inc.16$400
Pharmacosmos Therapeutics Inc.14$384
Incyte Corporation15$378
Regeneron Healthcare Solutions, Inc.13$371
GSK14$364
AbbVie14$344
Amgen11$321
Bayer13$319
Eisai Inc.14$313
Stemline Therapeutics Inc.8$304
Sanofi10$288
Pharmacyclics LLC, An Abbvie Company11$265
Exelixis Inc.7$235
E.r. Squibb & Sons, L.L.C.11$233
Seagen Inc.7$181
Tersera Therapeutics LLC6$177
Sobi, Inc7$172
Gilead(2 entities)7$168
Beigene USA, Inc.6$165
Taiho Oncology, Inc.6$160
Array Biopharma Inc6$147
Myovant Sciences Inc.4$144
EMD Serono, Inc.5$122
Genmab U.S., Inc.4$118
Myriad Genetic Laboratories, Inc.4$116
Ipsen Biopharmaceuticals, Inc4$102
Global Blood Therapeutics, Inc.1$100
Spectrum Pharmaceuticals Inc.4$91
Pharmaessentia USA Corporation3$84
Rigel Pharmaceuticals, Inc.3$81
Boehringer Ingelheim3$80
Morphosys, US Inc.3$71
Caris MPI, Inc.3$68
Coherus Oncology, Inc.3$68
Heron Therapeutics, Inc.2$66
Kyowa Kirin, Inc.3$65
ADC Therapeutics America, Inc.3$63
Puma Biotechnology, Inc.3$58
Mirati Therapeutics, Inc.2$54
Servier Pharmaceuticals LLC3$53
Agios Pharmaceuticals, Inc.2$51
CTI Biopharma Corp.3$50
Karyopharm Therapeutics Inc.2$48
Beone Medicines USA, Inc.2$43
Blueprint Medicines Corporation2$41
Celltrion USA Inc.1$40
Immunocore Limited1$38
Alnylam Pharmaceuticals Inc.2$35
Deciphera Pharmaceuticals Inc.2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,717 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$63,680
Medicare patients
45
Services billed
3,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$29,721
XareltoRivaroxaban15$8,348
Exemestane12$3,461
Enoxaparin Sodium12$2,832
Letrozole38$1,060
Warfarin Sodium65$575
Anastrozole31$459
Oxycodone Hcl19$443
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$300
Dexamethasone16$194
Albuterol Sulfate HfaAlbuterol Sulfate11$156
Prochlorperazine Maleate17$154
Lidocaine-PrilocaineLidocaine/Prilocaine13$149
Gabapentin20$137
Methadone Hcl14$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$685$29,72129 claims
Johnson & JohnsonXarelto$1,011$8,34815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in White Plains

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →